Inventiva S.A. (NASDAQ:IVA) Sees Large Decrease in Short Interest

Inventiva S.A. (NASDAQ:IVA) was the recipient of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 390,300 shares, a drop of 9.2% from the October 31st total of 429,900 shares. Based on an average daily volume of 207,600 shares, the short-interest ratio is presently 1.9 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IVA. HC Wainwright lowered their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 15th. Stifel Nicolaus decreased their price objective on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Finally, UBS Group started coverage on shares of Inventiva in a research note on Tuesday, November 12th. They set a “neutral” rating and a $3.00 price objective for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.25.

Inventiva Stock Up 1.9 %

Shares of NASDAQ IVA traded up $0.05 during midday trading on Monday, reaching $2.70. 5,925 shares of the company traded hands, compared to its average volume of 74,664. The stock’s 50-day simple moving average is $2.43 and its 200-day simple moving average is $2.61. Inventiva has a 12 month low of $1.53 and a 12 month high of $4.75.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC acquired a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.